Biotech

All Articles

ArsenalBio increases $325M, turns far from previous lead resource

.Arsenal Biosciences is going on up. The cell treatment provider has actually added $325 million in ...

Lilly- backed fat burning biotech documents IPO

.After elevating $170 million back in February, metabolic disease-focused BioAge Labs has filed to d...

Aelis' cannabis usage medicine fails phase 2b, steering Indivior to re-think $100M alternative

.Aelis Farma's hopes of safeguarding a simple, positive choice on a $100 million alternative settlem...

ProKidney standstills period 3 test not required for tissue treatment permission

.ProKidney has actually stopped some of a pair of phase 3 trials for its cell treatment for kidney i...

Vaxcyte surges on 'impressive' 31-valent PCV gain against Pfizer

.Vaxcyte introduced what professionals named "sensational" stage 1/2 records for its own 31-valent p...

Recursion's mind condition test reveals scant proof of effectiveness

.Recursion has actually discovered via an early exam of its tech-enabled technique to drug revelatio...

Acepodia, Pfizer click all together for chemistry-based cell therapy

.Contact it a case of good chemistry: Acepodia, a biotech based upon Nobel Champion scientific resea...

Praxis epilepsy medication reduces confiscations in phase 2 trial

.Practice Accuracy Medicines has scored one more midphase gain in epilepsy this year, along with its...

Three directors surrender as Dyne messages mixed records for DMD prospect

.After running away a professional hold several years back, Dyne Therapy has shown brand new stage 1...

Arrowhead fires off period 3 data in unusual metabolic disease before market encounter Ionis

.Arrowhead Pharmaceuticals has revealed its own hand in front of a potential showdown with Ionis, pu...